Dr. Shumway is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
18707 Hardy Oak Blvd
Ste 320
San Antonio, TX 78258Phone+1 210-545-6972Fax+1 210-545-1016
Education & Training
- San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 2005 - 2008
- National Capital ConsortiumResidency, Internal Medicine, 2002 - 2005
- College of Osteopathic Medicine of the PacificClass of 2002
Certifications & Licensure
- TX State License 2012 - 2026
- HI State License 2003 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 4 citationsConcomitant plasmapheresis and cladribine infusion for the treatment of life-threatening systemic lupus erythematosus.W. P. Delacruz, A. Cap, N. Shumway
Internal Medicine Journal. 2016-11-01 - 71 citationsPrimary Analysis of a Prospective, Randomized, Single-Blinded Phase II Trial Evaluating the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent RecurrenceElizabeth A. Mittendorf, Alexandros Ardavanis, James T. Symanowski, James L. Murray, Nathan M. Shumway
Annals of Oncology. 2016-03-30 - 34 citationsAE37: a novel T-cell-eliciting vaccine for breast cancerAlan K. Sears, Sonia A. Perez, Guy T. Clifton, Linda C. Benavides, Jeremy D. Gates
Expert Opinion on Biological Therapy. 2011-10-06
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: